Results 21 to 30 of about 280,086 (335)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

open access: yes, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht   +6 more
core   +3 more sources

RTEL1 gene polymorphisms and neuroblastoma risk in Chinese children

open access: yesBMC Cancer, 2023
Background Neuroblastoma, a neuroendocrine tumor originating from the sympathetic ganglia, is one of the most common malignancies in childhood. RTEL1 is critical in many fundamental cellular processes, such as DNA replication, DNA damage repair, genomic ...
Ting Zhang   +5 more
doaj   +1 more source

Neuroblastoma [PDF]

open access: yesJapanese Journal of Clinical Oncology, 2018
Neuroblastoma is one of the most common solid tumors in children and has a diverse clinical behavior that largely depends on the tumor biology. Neuroblastoma exhibits unique features, such as early age of onset, high frequency of metastatic disease at diagnosis in patients over 1 year of age and the tendency for spontaneous regression of tumors in ...
Akira, Nakagawara   +5 more
openaire   +2 more sources

Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells [PDF]

open access: yes, 2009
BACKGROUND: Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics analysis of gene expression data was used to identify chemoresistance-associated changes in neuroblastoma biology.
Barth, Susanne   +10 more
core   +6 more sources

Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11 [PDF]

open access: yes, 2005
Background: Loss of chromosome 11q defines a subset of high-stage aggressive neuroblastomas. Deletions are typically large and mapping efforts have thus far not lead to a well defined consensus region, which hampers the identification of positional ...
De Preter, K   +13 more
core   +3 more sources

Effective Alu repeat based RT-qPCR normalization in cancer cell perturbation experiments [PDF]

open access: yes, 2013
Background: Measuring messenger RNA (mRNA) levels using the reverse transcription quantitative polymerase chain reaction (RT-qPCR) is common practice in many laboratories.
Beckers, Anneleen   +13 more
core   +8 more sources

Anesthetic management of an infant with giant abdominal neuroblastoma

open access: yesBrazilian Journal of Anesthesiology, 2017
Neuroblastoma is the most common, non-central nervous system tumor of childhood. It has the potential to synthesize catecholamines. However, the presences of hypertension are uncommon.
Manuel Ángel Gómez-Ríos   +2 more
doaj   +1 more source

miR‐100 rs1834306 a > G polymorphism decreases neuroblastoma risk in Chinese children

open access: yesCancer Reports, 2023
Background Neuroblastoma is a common malignant tumor stemming from the sympathetic nervous system in children, which is often life‐threatening. The genetics of neuroblastoma remains unclear. Studies have shown that miRNAs participate in the regulation of
Yufeng Han   +7 more
doaj   +1 more source

Pyroptosis-Related Gene Signature Predicts the Prognosis and Immune Infiltration in Neuroblastoma

open access: yesFrontiers in Genetics, 2022
Neuroblastoma is the most common pediatric extracranial solid tumor. The 5-year survival rate for high-risk neuroblastoma is less than 50%, despite multimodal treatment.
Wanrong Li, Xin Li, Yuren Xia, Jian Wang
doaj   +1 more source

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. [PDF]

open access: yes, 2016
BackgroundNovel therapies are needed for children with high-risk and relapsed neuroblastoma. We hypothesized that MAPK/ERK kinase (MEK) inhibition with the novel MEK1/2 inhibitor binimetinib would be effective in neuroblastoma preclinical models ...
Liu, Yin   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy